Aims & Scope
Current Cancer Drug Targets aims to cover all the latest and outstanding developments in full spectrum of cancer drug discovery and development, including but not limited to cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel drug targets for human anticancer drug discovery continues to grow, this journal has become essential reading for all biomedical and pharmaceutical scientists involved in drug discovery and development. Its scope covers publications related to prevention, diagnosis and treatment of all types of human cancers in various of basic and translational researches, including cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, immunotherapy and combination therapy, stem cell, tumor environment, metabolism emphasizing on advanced mechanistic investigations.
Abstracted & Indexed in:
Archiving and Copyright:
"In view of the growing volume of literature, the role of high quality review journals has become
increasingly important. Current Drug Targets is an important journal in the field of medicinal
chemistry and drug design, which is strongly recommended to the scientific community."